Abbott Laboratories
reported fourth-quarter adjusted earnings that beat Wall Street estimates but sales fell 12% from a year earlier due to what the company called an “expected decline compared to the previous year.” same period last year for sales related to Covid-19 testing.”
Shares of Abbott (ticker: ABT) were down 1.8% in premarket trading.
